Insilico Medicine and SK Biopharmaceuticals launched an AI-based collaboration focused on neuroimmune disorders in the central nervous system. The agreement assigns Insilico’s Pharma.AI platform to target validation, generative chemistry, and molecule optimization, while SK retains development and commercialization responsibilities for resulting programs. The collaboration could generate up to $2.5 billion for Insilico, according to reported terms, reflecting the value placed on AI-led discovery-to-candidate progression when paired with a partner able to execute clinical development. SK will provide development and clinical capabilities, steering programs through late stages. Insilico’s approach, as described by founder/co-CEO Alex Zhavoronkov, is aimed at delivering real drug candidates rather than remaining at target discovery. SK is emphasizing its CNS expertise, noting its prior US commercialization of cenobamate (Xcopri) after FDA approval a year earlier. The deal underlines that neuroimmune biology remains an attractive target for AI acceleration, while also showing how big pharma-like capacity (development and commercialization) is still required to convert AI outputs into marketed therapies.